Overview

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Status:
RECRUITING

Trial end date:
2032-03-16

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus Calmette-Gurin (BCG) treated participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of high-risk non-muscle-invasive bladder cancer (HR-NMIBC).

Phase:

PHASE3

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

erdafitinib
Gemcitabine
Mitomycin